Building the bridge to global innovation

By: McKinsey & Company

China’s biopharma ecosystem is entering a new phase, rapidly shifting from a “fast follower” to a global source of first-in-class and best-in-class innovation across modalities and therapeutic areas. For biopharma leaders, investors, and healthcare stakeholders, understanding this transformation is now a strategic imperative, not a nice-to-have.

Following up BioCentury & BayHelix China Healthcare Summit, the analysis consolidates and deepens the key themes covered in McKinsey’s latest analysis of China’s healthcare ecosystem and biopharma innovation. All of the following insights are drawn directly from the report:

Topics Discussed in White Paper:

• China’s evolving balance between best-in-class and first-in-class innovation, detailing shifting priorities for homegrown scientific breakthroughs and global partnerships.
• How commercial and market access models are changing, and how these shifts influence patient access to therapies and value capture for stakeholders.
• Current cross-border investment and licensing trends, explaining their implications for international biotech collaboration and deal-making.
• Emerging strategies for sustainable growth in China’s biotech and medtech sectors, including approaches to funding, regulation, and global integration.

Download the full whitepaper now to access all insights.